<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981719</url>
  </required_header>
  <id_info>
    <org_study_id>Y2016-MS-001</org_study_id>
    <nct_id>NCT02981719</nct_id>
  </id_info>
  <brief_title>Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the therapeutic efficacy between simultaneous&#xD;
      gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer&#xD;
      (LAPC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      in the GEM- IRE group, before the IRE ablation started, patients received 1000 mg/m2&#xD;
      gemcitabine hydrochloride [Qilu pharmaceutical (Hainan) Co., Ltd. Haikou, China]&#xD;
      intravenously (over approximately 30 min).&#xD;
&#xD;
      In the IRE group, the IRE ablation was performed without gemcitabine intravenous infusion&#xD;
      before IRE.&#xD;
&#xD;
      The aim of this study was to evslusted the overall survival (OS), objective response rate&#xD;
      (ORR) and adverse events after simultaneous therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (number of adverse effects)</measure>
    <time_frame>3 month</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>12 months</time_frame>
    <description>Imaging evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) was defined using time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate antigen 19-9 (CA19-9)</measure>
    <time_frame>1 month</time_frame>
    <description>carbohydrate antigen 19-9 (CA19-9) levels were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success of ablation</measure>
    <time_frame>3 months</time_frame>
    <description>The technical success addressed whether the tumor was treated according to protocol and was covered completely by the ablation zone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>simultaneous gemcitabine and irreversible electroporation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine intravenous infusion prior to irreversible electroporation treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRE group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>percutaneous irreversible electroporation for locally advanced pancreatic cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>simultaneous gemcitabine and irreversible electroporation</intervention_name>
    <description>gemcitabine intravenous infusion prior to irreversible electroporation treatment</description>
    <arm_group_label>simultaneous gemcitabine and irreversible electroporation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>irreversible electroporation</intervention_name>
    <description>percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.</description>
    <arm_group_label>IRE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiologic confirmation of unresectable locally advanced pancreatic cancer by at least&#xD;
             CT of chest and abdomen&#xD;
&#xD;
          -  Screening must be performed no longer than 2 weeks prior to study inclusion&#xD;
&#xD;
          -  Maximum tumor diameter ≤ 5 cm&#xD;
&#xD;
          -  Histological or cytological confirmation of pancreatic adenocarcinoma;&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  PS-classification 0 - 2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to definite inclusion;&#xD;
&#xD;
          -  Hemoglobin level ≥ 115 g/L&#xD;
&#xD;
          -  Platelet count ≥ 100*109/l&#xD;
&#xD;
          -  Neutrophil count ≥ 2×109/L;&#xD;
&#xD;
          -  White blood cell count ≥ 4 ×109/L;&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  Prothrombin time or INR &lt; 1.5 x ULN&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable pancreatic adenocarcinoma as discussed by our multidisciplinary&#xD;
             hepatobiliary team&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  History of cardiac disease:&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for&#xD;
             antihypertensive regimen are permitted)&#xD;
&#xD;
          -  Compromised liver function (e.g. signs of portal hypertension, INR &gt; 1,5 without use&#xD;
             of anticoagulants, ascites)&#xD;
&#xD;
          -  Uncontrolled infections (&gt; grade 2 NCI-CTC version 3.0)&#xD;
&#xD;
          -  Pregnant. Women of childbearing potential must have a negative pregnancy test&#xD;
             performed within 7 days of the start of treatment&#xD;
&#xD;
          -  Allergy to contrast media&#xD;
&#xD;
          -  Any implanted stimulation device&#xD;
&#xD;
          -  Any implanted metal stent/device within the area of ablation that cannot be removed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FUDA Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

